source
- Alzheon seeks up to $500M in new financing after Phase 3 setback for Alzheimer’s drugAlzheon, a biotech based in Framingham, Massachusetts, has been pursuing an Alzheimer’s therapy for more than a decade. Its lead candidate recently failed to achieve the primary goals in a Phase 3…
- FDA plans study on barriers to women's enrollment in pregnancy exposure registries and announces PRV fee ratesThe Food and Drug Administration said it will conduct research into perceived barriers that limit women’s participation in pregnancy exposure registries. It also released the fee schedule for prio…